AU748870B2 - Method of inhibiting membrane-type matrix metalloproteinase - Google Patents

Method of inhibiting membrane-type matrix metalloproteinase Download PDF

Info

Publication number
AU748870B2
AU748870B2 AU34576/99A AU3457699A AU748870B2 AU 748870 B2 AU748870 B2 AU 748870B2 AU 34576/99 A AU34576/99 A AU 34576/99A AU 3457699 A AU3457699 A AU 3457699A AU 748870 B2 AU748870 B2 AU 748870B2
Authority
AU
Australia
Prior art keywords
cmt
mmp
tetracycline
activity
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34576/99A
Other languages
English (en)
Other versions
AU3457699A (en
Inventor
Lorne M. Golub
Hsi-Ming Lee
Tuula Salo
Timo Sorsa
Olli Teronen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of AU3457699A publication Critical patent/AU3457699A/en
Application granted granted Critical
Publication of AU748870B2 publication Critical patent/AU748870B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU34576/99A 1998-03-31 1999-03-30 Method of inhibiting membrane-type matrix metalloproteinase Ceased AU748870B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/052222 1998-03-31
US09/052,222 US6277061B1 (en) 1998-03-31 1998-03-31 Method of inhibiting membrane-type matrix metalloproteinase
PCT/US1999/006972 WO1999049871A1 (en) 1998-03-31 1999-03-30 Method of inhibiting membrane-type matrix metalloproteinase

Publications (2)

Publication Number Publication Date
AU3457699A AU3457699A (en) 1999-10-18
AU748870B2 true AU748870B2 (en) 2002-06-13

Family

ID=21976191

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34576/99A Ceased AU748870B2 (en) 1998-03-31 1999-03-30 Method of inhibiting membrane-type matrix metalloproteinase

Country Status (8)

Country Link
US (2) US6277061B1 (enExample)
EP (1) EP1079837A4 (enExample)
JP (1) JP2002509889A (enExample)
KR (1) KR20010042322A (enExample)
AU (1) AU748870B2 (enExample)
CA (1) CA2320260A1 (enExample)
NZ (1) NZ506153A (enExample)
WO (1) WO1999049871A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506740B1 (en) * 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
EP1174129A1 (en) * 2000-07-17 2002-01-23 Zenner, Hans Peter, Prof. Dr. med. Use of a matrix-metalloprotease inhibitor for the treatment of cancer
EP2329826A1 (en) 2001-07-13 2011-06-08 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of multiple sclerosis
CA2462572C (en) * 2001-10-05 2008-11-18 Tetragenex Pharmaceuticals, Inc. Tetracycline derivatives and methods of use thereof
IL162213A0 (en) * 2001-12-03 2005-11-20 Novacea Inc Pharmaceutical compositions containing active vitamin d compounds
WO2003053447A1 (en) * 2001-12-20 2003-07-03 Hanauske-Abel Hartmut M Treatment for averting or delaying premature delivery
EP2322501B1 (en) 2002-01-08 2015-08-05 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
KR101014918B1 (ko) 2002-03-08 2011-02-15 파라테크 파마슈티컬스, 인크. 아미노-메틸 치환된 테트라시클린 화합물
EP2481723A3 (en) 2002-03-21 2013-02-13 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP2250887B1 (en) * 2002-03-29 2013-04-24 The Research Foundation Of The State University Of New York Use of non-antibacterial tetracycline analog CMT-1002 and formulations thereof for the treatment of bacterial exotoxins
EP2345637A3 (en) 2002-07-12 2012-02-15 Paratek Pharmaceuticals, Inc. 3, 10, and 12a substituted tetracycline compounds
US20040170621A1 (en) * 2002-08-30 2004-09-02 Roodman G. David Method of resisting osteoclast formation
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
EP1562608A4 (en) 2002-10-24 2010-09-01 Paratek Pharm Innc METHOD OF USE OF SUBSTITUTED TETRACYCLINE COMPOUNDS FOR MODULATING THE RNA
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2531728A1 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
WO2005070878A1 (en) * 2004-01-15 2005-08-04 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
EP1805134B1 (en) 2004-10-25 2012-06-20 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP2269978A3 (en) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2007014154A2 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
US20070142337A1 (en) * 2005-12-15 2007-06-21 The Regents Of The University Of California Treatment of inflammation and organ dysfunction
IL302749A (en) 2006-12-21 2023-07-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
TR201818983T4 (tr) * 2006-12-21 2019-01-21 Paratek Pharm Innc İnflamatuvar Cilt Bozukluklarının Tedavisine Yönelik Olarak Sübstitüe Edilmiş Tetrasiklin Bileşikleri
EP2213655A1 (en) 2007-04-27 2010-08-04 Paratek Pharmaceuticals, Inc. Methods For Purifying Aminoalkyl Tetracycline Compounds
CN101811980A (zh) * 2007-07-06 2010-08-25 帕拉特克药品公司 合成取代的四环素化合物的方法
TW202216656A (zh) 2008-05-19 2022-05-01 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
CN105367440A (zh) 2008-08-08 2016-03-02 四相制药公司 C7-氟取代的四环素化合物
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
PL2470500T3 (pl) 2009-08-28 2018-03-30 Tetraphase Pharmaceuticals, Inc. Związki tetracyklinowe
JP5820462B2 (ja) 2010-03-31 2015-11-24 テトラフェース ファーマシューティカルズ，インコーポレイテッド 多環式テトラサイクリン化合物
HRP20191295T8 (hr) 2011-05-12 2020-02-07 Paratek Pharmaceuticals, Inc. Kristalne soli amida (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksilne kiseline i postupci uporabe istih
SMT201900096T1 (it) 2012-08-31 2019-02-28 Tetraphase Pharmaceuticals Inc Composti di tetracicline
JP7492335B2 (ja) 2016-10-19 2024-05-29 テトラフェース ファーマシューティカルズ，インコーポレイテッド エラバサイクリンの結晶形
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012717A2 (en) * 1991-01-15 1992-08-06 A composition containing a tetracycline and use for inhibiting angiogenesis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
DE69304292T2 (de) * 1992-11-17 1997-01-02 Univ New York Tetracycline inclusive nicht antimicrobiel wirksame, chemisch modifizierte Tetracycline hemmende exzessive Kollagenquervernetzung bei Diabetes
US5668122A (en) * 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
GB9615976D0 (en) 1996-07-30 1996-09-11 Center For Clinical & Basic Re The use of proteinase inhibitors for the prevention or reduction of bone resorption
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012717A2 (en) * 1991-01-15 1992-08-06 A composition containing a tetracycline and use for inhibiting angiogenesis

Also Published As

Publication number Publication date
AU3457699A (en) 1999-10-18
WO1999049871A8 (en) 1999-12-02
EP1079837A4 (en) 2003-07-02
US20020045603A1 (en) 2002-04-18
EP1079837A1 (en) 2001-03-07
NZ506153A (en) 2003-10-31
US6277061B1 (en) 2001-08-21
CA2320260A1 (en) 1999-10-07
JP2002509889A (ja) 2002-04-02
WO1999049871A1 (en) 1999-10-07
KR20010042322A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
AU748870B2 (en) Method of inhibiting membrane-type matrix metalloproteinase
AU729886B2 (en) Method of inhibiting cancer growth
ES2241124T3 (es) Actividad inhibidora de serin-proteinasa mediante tetraciclina hidrofoba.
ES2237945T3 (es) Combinacion de bisfosfonato y tetraciclina.
DE60036490T2 (de) Zusammensetzung zur behandlung von prostatakrebs
Davies et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
Johnson et al. Matrix metalloproteinases
JP2676080B2 (ja) 非抗バクテリア性テトラサイクリン組成物
ES2578618T3 (es) Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
DE69322659T2 (de) Pharmazeutische zubereitung enthaltend eine beta-lactam antibiotikum abbauende verbindung, und deren verwendung
Lee et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer
US6429204B1 (en) Method of inhibiting cancer growth
EP0871438B1 (en) Use of alpha-hydroxy acids in the manufacture of a medicament for the treatment of inflammation
US20070027064A1 (en) Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
US6033664A (en) Use of a preparation comprising a plasminogen activator to improve wound healing
Hanemaaijer et al. Inhibition of matrix metalloproteinases (MMPs) by tetracyclines
Schneider et al. Tetracyclines inhibit intracellular muscle proteolysis in vitro
Rathna et al. Recent Insights of Matrix Metalloproteinase Inhibitors in Therapeutic Applications
MXPA99006554A (en) Method of inhibiting cancer growth
Acid Correlation of Antiangiogenic and Antitumor Efficacy of
Konttinen et al. Inhibition of matrix metalloproteinases (MMPs) by tetracyclines

Legal Events

Date Code Title Description
SREP Specification republished
TH Corrigenda

Free format text: IN VOL 16, NO 18, PAGE(S) 4707 UNDER THE HEADING APPLICATIONS ACCEPTED UNDER THE NAME THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, SERIAL NO. 748870, INID (72), ADD INVENTORS LEE, H-M., SORSA, T., TERONEN, O., SALO, T.

FGA Letters patent sealed or granted (standard patent)